Postdoctoral Research Fellow
Job posting number: #7054423 (Ref:13f2ea48)
Posted: November 20, 2018
Application Deadline: Open Until Filled
Two postdoctoral fellow positions are available in the laboratory of Dr. Li (Lily) Wang at the Cleveland Clinic Taussig Cancer Institute's Department of Translational Hematology & Oncology Research located within the Lerner Research Insitute (LRI). https://my.clevelandclinic.org/departments/cancer/depts/thor)
The Wang laboratory is engaging in cross-disciplinary studies by collaborating with basic and clinical researchers from the LRI including investigators in the Department of Inflammation and Immunology and the CASE Comprehensive Cancer Center, affiliated with CASE Western Reserve University.
Immune-checkpoint blockade (ICB) therapies have revolutionized the field of Cancer Immunotherapy. However, the low response rate in a majority of patients indicates the urgent need to identify and target additional checkpoint regulators. The Wang lab was the first group to demonstrate that a new immune-checkpoint protein “V domain Immunoglobulin Suppressor of T cell Activation” (VISTA) is a promising target for cancer immunotherapy (1 – 5). Current projects are elucidating the signaling mechanisms of VISTA in controlling tumor-associated myeloid cells and cytotoxic T cells, and designing innovative approaches to target VISTA for cancer therapy.
1.Wang L, RubinsteinR, Lines LJ, Wasiuk A, AhonenC, GuoYX, LuLF, Gondek D, WangY, Fava RA, Fiser A, Almo S and Noelle RJ. (2011) VISTA, a novel Ig-superfamily ligand that negatively regulates T cell responses, J Exp Med. 208(3):577-92. PMC3058578
2. Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, Noelle RJ, Wang L (2014) VISTA regulates the development of protective anti-tumor immunity. Cancer Research, 74:1933-1944. PMC4116689
3. Wang L, Le Mercier I, Putra J, Chen W, Liu J, Schenk AD, Nowak EC, Suriawinata AA, Li J, Noelle RJ. (2014) Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. PNAS. (41):14846-51 PMC4205642
4. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller H, Guleria I, Barth RJ, Huang YH, Wang L (2015) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. PNAS. 112(21):6682-7, PMC4450438
5. Xu W, Táº¡ MH, Malarkannan S, Wang L(2018) Review: The structure, expression, and function of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cellular & Molecular Immunology. 2018 May 15(5):438-446 PMC6068175
We therefore seek talented and committed candidates with a recent Ph.D. in Biochemistry, Cell Biology or Immunology, and expertise in Bioinformatics and Computational Biology to join our team and make significant contributions to the field of Cancer Immunotherapy. Interested candidates should submit CV, a statement of research interests in a cover letter, and a list of three references.
Please send your curriculum vitae and contact information for 3 references to John Pellecchia MS, Department Administrator, at email@example.com
Cleveland Clinic is pleased to be an equal employment/affirmative action employer: Women/Minorities/Veterans/Individuals with Disabilities. Smoke/drug free environment.